Life sciences company Bio-Techne (NASDAQ: TECH) will be reporting results this Wednesday before market open. Here’s what investors should know.
Bio-Techne met analysts’ revenue expectations last quarter, reporting revenues of $316.2 million, up 4.2% year on year. It was a mixed quarter for the company, with an impressive beat of analysts’ EPS estimates.
Is Bio-Techne a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting Bio-Techne’s revenue to grow 2.9% year on year to $314.9 million, improving from the 1.6% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.50 per share.
The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Bio-Techne has missed Wall Street’s revenue estimates five times over the last two years.
Looking at Bio-Techne’s peers in the research tools & consumables segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Mettler-Toledo delivered year-on-year revenue growth of 3.9%, beating analysts’ expectations by 2.9%, and Thermo Fisher reported revenues up 3%, topping estimates by 1.6%. Mettler-Toledo traded down 3% following the results while Thermo Fisher was up 11.3%.
Read our full analysis of Mettler-Toledo’s results here and Thermo Fisher’s results here.
The euphoria surrounding Trump’s November win lit a fire under major indices, but potential tariffs have caused the market to do a 180 in 2025. While some of the research tools & consumables stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.3% on average over the last month. Bio-Techne is up 6.3% during the same time and is heading into earnings with an average analyst price target of $66.50 (compared to the current share price of $54.80).
Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
